PD-L1 Expression Testing Won’t Be a Must for Opdivo, but Clarification Needed: Chuikyo

Healthcare Provider Reps at Chuikyo Meeting on Dec. 14 PD-L1 expression testing is unlikely to be a “prerequisite” for the use of Ono Pharmaceutical’s anti-PD-1 antibody Opdivo (nivolumab), but medical institutions would be required to explain why they cannot conduct...read more